PE20200724A1 - Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre - Google Patents

Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre

Info

Publication number
PE20200724A1
PE20200724A1 PE2020000245A PE2020000245A PE20200724A1 PE 20200724 A1 PE20200724 A1 PE 20200724A1 PE 2020000245 A PE2020000245 A PE 2020000245A PE 2020000245 A PE2020000245 A PE 2020000245A PE 20200724 A1 PE20200724 A1 PE 20200724A1
Authority
PE
Peru
Prior art keywords
treatment
pyruvate kinase
blood disorders
kinase activators
halogen
Prior art date
Application number
PE2020000245A
Other languages
English (en)
Inventor
Giovanni Cianchetta
Tao Liu
Anil Kumar Padyana
Zhihua Sui
Zhenwei Cai
Dawei Cui
Jingjing Ji
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of PE20200724A1 publication Critical patent/PE20200724A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Abstract

Compuestos tiazolo-pirrolo-piridazinona de formula (I), donde R1 es H, alquilo, haloalquilo, entre otros; R2 y Q son heteroarilo monociclico de 5 o 6 miembros, entre otros; Ra y Rb son H, halogeno, CN, NO2, entre otros; Rj y Rk son H, halogeno, CN, entre otros. Dichos compuestos activan la enzima piruvato quinasa y son utiles en el tratamiento de trastornos de la sangre tales como anemia hemolitica, talasemia, entre otros. Tambien esta referida a composiciones farmaceuticas.
PE2020000245A 2017-08-15 2018-08-15 Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre PE20200724A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
PCT/US2018/000128 WO2019035864A1 (en) 2017-08-15 2018-08-15 PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Publications (1)

Publication Number Publication Date
PE20200724A1 true PE20200724A1 (es) 2020-07-21

Family

ID=63524352

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000245A PE20200724A1 (es) 2017-08-15 2018-08-15 Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre

Country Status (32)

Country Link
US (7) US11464775B2 (es)
EP (4) EP3668512B1 (es)
JP (4) JP7301040B2 (es)
KR (3) KR102642408B1 (es)
CN (3) CN111032046B (es)
AU (3) AU2018316587B2 (es)
BR (2) BR112020003262A2 (es)
CA (2) CA3072455A1 (es)
CL (1) CL2020000375A1 (es)
CO (2) CO2020002959A2 (es)
CR (1) CR20200123A (es)
CY (1) CY1124953T1 (es)
DK (2) DK3668513T3 (es)
EC (1) ECSP20018487A (es)
ES (2) ES2905100T3 (es)
FI (1) FI3668512T3 (es)
HR (2) HRP20220039T1 (es)
HU (2) HUE057178T2 (es)
IL (3) IL272599B (es)
LT (2) LT3668512T (es)
MD (1) MD3668513T2 (es)
MX (2) MX2020001833A (es)
PE (1) PE20200724A1 (es)
PH (1) PH12020500343A1 (es)
PL (2) PL3668512T3 (es)
PT (2) PT3668512T (es)
RS (2) RS62871B1 (es)
SG (2) SG11202001353PA (es)
SI (2) SI3668513T1 (es)
TW (3) TWI796353B (es)
UA (1) UA126292C2 (es)
WO (3) WO2019035864A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
AU2018316587B2 (en) 2017-08-15 2023-05-11 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020167976A1 (en) * 2019-02-13 2020-08-20 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
TW202115202A (zh) * 2019-06-26 2021-04-16 日商日產化學股份有限公司 電荷輸送性塗料
US20230374017A1 (en) * 2020-07-21 2023-11-23 The Regents Of The University Of Michigan Compositions and methods for activating pyruvate kinase
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
US11566030B2 (en) 2021-02-08 2023-01-31 Global Blood Therapeutics, Inc. Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
WO2023052783A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
WO2023091414A1 (en) * 2021-11-16 2023-05-25 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
TR200200928T2 (tr) 1999-07-30 2002-09-23 Abbott Gmbh & Co.Kg 2-pirazolin-5-on terkipleri
KR100692232B1 (ko) 1999-09-04 2007-03-09 아스트라제네카 아베 피루베이트 탈수소효소 활성을 증가시키는 치환된 ｎ-페닐2-히드록시-2-메틸-3,3,3-트리플루오로프로판아미드 유도체
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
BRPI0916295A2 (pt) * 2008-07-23 2019-09-24 Vertex Pharma inibidores de pirazolopiridina tricíclica cinase
US8420649B2 (en) * 2008-08-29 2013-04-16 Amgen Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
JP5632379B2 (ja) 2008-10-09 2014-11-26 アメリカ合衆国 ヒトピルビン酸キナーゼ活性化剤
EP2417123A2 (en) * 2009-04-06 2012-02-15 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
NZ622505A (en) 2009-06-29 2015-12-24 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
TW201307324A (zh) 2010-12-06 2013-02-16 Glaxo Group Ltd 化合物
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
ES2746558T3 (es) 2011-05-03 2020-03-06 Agios Pharmaceuticals Inc Activadores de piruvato cinasa R para uso en terapia
ES2829374T3 (es) 2011-05-03 2021-05-31 Agios Pharmaceuticals Inc Uso de activadores de piruvato quinasa para aumentar la vida útil de los glóbulos rojos de la sangre y tratar la anemia
WO2012151448A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
CA3088328A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
AU2012284088B2 (en) * 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
JP6362610B2 (ja) 2012-11-08 2018-07-25 アジオス ファーマシューティカルズ， インコーポレイテッド 治療用化合物及び組成物並びにｐｋｍ２調節剤としてのそれらの使用
JP2016506943A (ja) * 2013-01-30 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類
MX365950B (es) * 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
SG11202001166RA (en) 2017-08-15 2020-03-30 Inflazome Ltd Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
AU2018316587B2 (en) 2017-08-15 2023-05-11 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
TW201920194A (zh) 2017-08-15 2019-06-01 美商艾伯維有限公司 大環ｍｃｌ-１抑制劑及使用方法
AR112475A1 (es) 2017-08-15 2019-10-30 Agios Pharmaceuticals Inc Moduladores de piruvato quinasas y uso de los mismos
WO2020167976A1 (en) * 2019-02-13 2020-08-20 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Also Published As

Publication number Publication date
AU2018316588A1 (en) 2020-02-20
KR20230127364A (ko) 2023-08-31
HUE057178T2 (hu) 2022-04-28
US20200207785A1 (en) 2020-07-02
KR20200054200A (ko) 2020-05-19
AU2018316587A1 (en) 2020-02-20
WO2019035864A8 (en) 2019-03-28
CA3071993A1 (en) 2019-02-21
US11872225B2 (en) 2024-01-16
US20220233541A1 (en) 2022-07-28
HRP20230452T1 (hr) 2023-07-21
ECSP20018487A (es) 2020-05-29
TW202323258A (zh) 2023-06-16
EP3668513B1 (en) 2021-11-10
CY1124953T1 (el) 2023-01-05
TWI796353B (zh) 2023-03-21
US11040036B2 (en) 2021-06-22
DK3668512T3 (da) 2023-05-22
JP2023027276A (ja) 2023-03-01
SI3668512T1 (sl) 2023-06-30
US11590132B2 (en) 2023-02-28
EP3668512A1 (en) 2020-06-24
CR20200123A (es) 2020-06-29
BR112020003254A2 (pt) 2020-10-27
TW201920203A (zh) 2019-06-01
CN111032046B (zh) 2023-09-26
WO2019035863A8 (en) 2019-03-28
WO2019035865A1 (en) 2019-02-21
IL272597B (en) 2022-06-01
US20220395503A1 (en) 2022-12-15
CO2020002961A2 (es) 2020-04-13
PL3668512T3 (pl) 2023-06-19
BR112020003262A2 (pt) 2020-09-01
SG11202001262QA (en) 2020-03-30
ES2944545T3 (es) 2023-06-22
JP2023052478A (ja) 2023-04-11
IL272599A (en) 2020-03-31
MX2020001833A (es) 2020-07-22
TW201919631A (zh) 2019-06-01
US20210077490A1 (en) 2021-03-18
CL2020000375A1 (es) 2020-12-11
HRP20220039T1 (hr) 2022-04-15
EP3668513A1 (en) 2020-06-24
CA3072455A1 (en) 2019-02-21
SG11202001353PA (en) 2020-03-30
PT3668512T (pt) 2023-05-22
RU2020110573A3 (es) 2021-12-24
DK3668513T3 (da) 2022-01-10
US20230226055A1 (en) 2023-07-20
CO2020002959A2 (es) 2020-04-13
WO2019035864A1 (en) 2019-02-21
US11464775B2 (en) 2022-10-11
RU2020110573A (ru) 2021-09-16
UA126292C2 (uk) 2022-09-14
PL3668513T3 (pl) 2022-03-21
TWI790271B (zh) 2023-01-21
US20200206225A1 (en) 2020-07-02
US11957680B2 (en) 2024-04-16
RS64221B1 (sr) 2023-06-30
CN111032046A (zh) 2020-04-17
RS62871B1 (sr) 2022-02-28
WO2019035863A1 (en) 2019-02-21
LT3668513T (lt) 2022-03-25
IL272599B (en) 2022-08-01
EP3668881B1 (en) 2023-10-04
IL292530A (en) 2022-06-01
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
LT3668512T (lt) 2023-06-12
SI3668513T1 (sl) 2022-04-29
ES2905100T3 (es) 2022-04-07
AU2018316587B2 (en) 2023-05-11
JP7275107B2 (ja) 2023-05-17
PH12020500343A1 (en) 2021-02-08
JP2020531432A (ja) 2020-11-05
US20210130371A1 (en) 2021-05-06
AU2023202772A1 (en) 2023-05-18
CN117186119A (zh) 2023-12-08
IL272597A (en) 2020-03-31
IL292530B2 (en) 2023-06-01
KR20200054199A (ko) 2020-05-19
HUE061910T2 (hu) 2023-08-28
JP2020531443A (ja) 2020-11-05
MD3668513T2 (ro) 2022-04-30
FI3668512T3 (fi) 2023-05-12
EP4026838A1 (en) 2022-07-13
CN111032045B (zh) 2023-08-15
MX2020001832A (es) 2020-07-22
WO2019035865A8 (en) 2019-03-28
AU2018316588B2 (en) 2023-02-02
JP7301040B2 (ja) 2023-06-30
US11364240B2 (en) 2022-06-21
KR102642408B1 (ko) 2024-02-28
EP3668881A1 (en) 2020-06-24
EP3668512B1 (en) 2023-02-15
CN111032045A (zh) 2020-04-17

Similar Documents

Publication Publication Date Title
PE20200724A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
PE20171329A1 (es) Agentes inmunorreguladores
PE20210642A1 (es) Inhibidores de pd-1/pd-l1
PE20170662A1 (es) Compuestos de aminopiridiloxipirazol
PE20180160A1 (es) Sulfonilureas y compuestos relacionados y uso de estos
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
CL2015000942A1 (es) Compuestos de benceno sustituido.
PE20171623A1 (es) Agentes inmunomoduladores
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
PE20170268A1 (es) Compuestos de heteroarilo para la inhibicion de cinasa
PE20141974A1 (es) Compuestos de heterociclilo
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
PE20170004A1 (es) Inhibidores de biaril cinasa
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20160664A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
PE20151274A1 (es) Inhibidores de erk y sus usos
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
PE20151413A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
PE20210373A1 (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos